interferon alfa-2a


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to interferon alfa-2a: interferon alfa-2b, Roferon

interferon

 [in″ter-fēr´on]
any of a family of glycoprotein biological response modifiers used as antineoplastic agents and immunoregulators; they inhibit cellular growth, alter the state of cellular differentiation, have effects on the cell cycle, interfere with oncogene expression, alter cell surface antigen expression, have effects on antibody production, and regulate cytotoxic effector cells.
interferon-α the major interferon produced by virus-induced leukocyte cultures; its primary producer cells are null cells, and its major activities are antiviral activity and activation of NK cells.
interferon alfa-2a a synthetic form of interferon-α produced by recombinant technology that acts as a biologic response modifier, used as an antineoplastic in the treatment of hairy cell leukemia and AIDS-related Kaposi's sarcoma; administered intramuscularly or subcutaneously.
interferon alfa-2b a synthetic form of interferon-α produced by recombinant technology that acts as a biologic response modifier, used in the treatment of veneral warts, hepatitis B, and chronic hepatitis C and as an antineoplastic in the treatment of hairy cell leukemia, malignant melanoma, non-Hodgkin's lymphomas, multiple myeloma, mycosis fungoides, and AIDS-related Kaposi's sarcoma; administered intramuscularly, subcutaneously, or intralesionally.
interferon alfacon-1 a synthetic interferon related to both α and β interferons, produced by recombinant DNA technology; used in the treatment of chronic hepatitis C virus infection, administered subcutaneously.
interferon alfa-n3 a highly purified mixture of natural human interferon proteins that acts as a biologic response modifier; used in the treatment of venereal warts, administered intralesionally.
interferon-β the major interferon produced by double-stranded RNA-induced fibroblast cultures; the major producer cells are fibroblasts, epithelial cells, and macrophages, and its major activity is antiviral.
interferon beta-1a a synthetic form of interferon-β produced by recombinant DNA techniques that acts as a biologic response modifier; used in the treatment of relapsing forms of multiple sclerosis; administered intramuscularly.
interferon beta-1b a synthetic modified form of interferon-β produced by recombinant DNA techniques; used as a biologic response modifier in the treatment of relapsing forms of multiple sclerosis; administered subcutaneously.
interferon-γ the major interferon produced by lymphocyte cultures that have been immunologically stimulated by mitogens or antigens; the major producer cells are T lymphocytes, and its major activity is immunoregulation.
interferon gamma-1b a synthetic form of interferon-γ produced by recombinant technology that acts as a biologic response modifier and antineoplastic. It is used to reduce the frequency and severity of serious infections associated with chronic granulomatous disease, administered subcutaneously.

interferon alfa-2a

(ăl′fə-)
n.
A synthetic form of interferon alpha produced by recombinant DNA technology, used in the treatment of chronic hepatitis C, hairy cell leukemia, and certain types of chronic myelogenous leukemia.

interferon alfa-2a

a synthetic form of interferon-α produced by recombinant technology that acts as a biological response modifier, used as an antineoplastic in the treatment of hairy cell leukemia and AIDS-related Kaposi's sarcoma. It is administered intramuscularly or subcutaneously.

interferon alfa-2a, recombinant

a parenteral antineoplastic drug.
indications It is administered in the treatment of AIDS-related Kaposi's sarcoma, hairy cell and chronic myelogenous leukemia, and chronic hepatitis C. It also has a variety of unlabeled or investigational uses.
contraindications Caution is recommended in prescribing this product for patients with severe cardiovascular disease.
adverse effects Among reported adverse effects are influenza-like symptoms, particularly at the beginning of therapy with the drug; confusion; dizziness; nervousness; depression; anorexia; nausea; vomiting; diarrhea; throat inflammation; dry and itching skin; alopecia; diaphoresis; blood pressure changes; and tachycardia.
References in periodicals archive ?
A randomized trial comparing pegylated interferon alfa-2b to pegylated interferon alfa-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
One described the treatment of 48 infants with aggressive hemangiomas with interferon alfa-2a that had no benzyl alcohol, and there was no incidence of neurotoxicity.
Loss of the hepatitis B e antigen (HBeAg) and hepatitis B viral (HBV) DNA levels below 200 IU / mL after 48 weeks of therapy occurred in 18% of patients randomized to entecavir (Baraclude) and pegylated interferon alfa-2a (Pegasys), vs.
Discoverer and developer of small molecule drugs Achillion Pharmaceuticals Inc (Nasdaq:ACHN) on Saturday announced that in the second segment of its Phase 2a trial of ACH-1625, 94% to 100% of patients with treatment naive genotype 1 chronic hepatitis C virus (HCV) achieved a complete early virologic response (cEVR) after 12 weeks of treatment with ACH-1625 in combination with pegylated interferon alfa-2a and ribavirin (P/R).
Since 2006, when the innovator obtained the first product patent (incidentally, the patent was also the first of its kind after India started honoring product patents in 2005) for pegylated interferon alfa-2a (Pegasys), the company has involved in at least a dozen patent infringement disputes in Indian courts.
They had been randomized to the placebo arm of a pegylated interferon alfa-2a plus ribavirin trial.
Task 23) pegylated interferon alfa-2a - Solution for injection 1 amp / vial and 0.
Neither of the studies compared pegylated interferon alfa-2a (Pegasys) directly with pegylated interferon alfa-2b (Peg-Intron).
The clinical trial has advanced into the second segment of a Phase IIa, randomised, double-blind trial evaluating the safety, tolerability and antiviral activity of oral ACH-1625 in combination with standard of care (SOC) consisting of pegylated interferon alfa-2a and ribavirin.
Peginterferon alfa-2a plus ribavirin is significantly more effective in treating hepatitis C infection in HIV-infected patients than is interferon alfa-2a plus ribavirin, reported Dr.
DALLAS -- Chronic hepatitis C patients with cirrhosis had significantly better virologic responses after 48 weeks of pegylated interferon than they did after interferon alfa-2a, Dr.
All patients also received a standard dosage of 180 [micro]g pegylated interferon alfa-2a given as a subcutaneous injection once a week.